<DOC>
	<DOCNO>NCT00793650</DOCNO>
	<brief_summary>The goal study evaluate safety melphalan autologous PBSCT ( peripheral blood stem cell transplantation - stem cell come body ) combination bortezomib , new FDA approve drug use treat myeloma .</brief_summary>
	<brief_title>Combination High Dose Melphalan Autologous Peripheral Blood Stem Cell ( PBSC ) Transplant With Bortezomib Multiple Myeloma : A Dose Schedule Finding Study</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Patients multiple myeloma eligible autologous peripheral blood progenitor transplant Male female subject age 18 70 year . Patient give informed consent prior study related procedure knowledge consent withdrawn anytime without prejudice future medical care Patient , investigator 's opinion , willing able comply protocol requirement Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agree use acceptable method contraception duration study . Biopsy proven diagnosis multiple myeloma bone marrow aspirate biopsy prior study initiation Patient achieve less 90 % disease reduction previous treatment prior transplant ( measure serum urine protein electrophoresis ) 5 % plasma cell bone marrow , patient progress 5 % plasma cell bone marrow . Karnofsky Performance Status score ≥ 60 % Patient meet follow laboratory requirement prior Day 4 Platelet count ≥ 50 , 000/mm3 Absolute Neutrophil Count ≥ 500/mm3 Hemoglobin ≥ 10 g/dL ( transfusion allow meet criterion ) Calculated creatinine clearance ≥ 30mL/min Toxic effect previous therapy surgery resolve Grade 2 well Unsupportable anemia &lt; 10b/dL Patient calculate measured creatinine clearance &lt; 30mL/min within 14 day enrollment Patient ≥ Grade 2 peripheral neuropathy within 14 day enrollment Patient hypersensitivity bortezomib , boron mannitol Patient allergic reaction melphalan chlorambucil Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum βhuman chorionic gonadotropin ( βhCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . Patient receive investigational drug 14 day enrollment Serious medical psychiatric illness likely interfere participation clinical study Cardiac pulmonary dysfunction patient meet institutional pretransplant evaluation criterion Known central nervous system involvement suspicion involvement Myeloma Other active malignancy ( exception basal squamous cell skin cancer ) within 5 year study entry . Patients treated prostate cervical cancer situ 2 year therapy remain free disease may enter study investigator 's discretion . Known HIV positive , HIV1 positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Peripheral Blood Stem Cell Transplant</keyword>
</DOC>